AVEO Pharmaceuticals, Inc. (AVEO)

[Doctor Detroit]

A whole lot lately about Notch3 and cancer..."more recent findings suggest that Notch3 signaling may play an important role in oncogenesis, tumor maintenance, and resistance to chemotherapy."

https://www.ncbi.nlm.nih.gov/pubmed/29622701

AVEO patent for its Notch3 antibody is a composition of matter patent. In other words, for the exact chemical make-up of the antibody (does not address use of the antibody). Very wide patent grant.

AVEO states they are looking for a partner for Av-353 for PAH...I bet part of the hold up is licensees want the rights to the patent for ALL applications, not just PAH.